Assembly committee approves bill restricting biosimilar substitutions

08/23/2013 | California Healthline · Drug Store News

A bill that would require pharmacists to inform prescribers when they substitute a biosimilar drug for a biologic medication was approved by a California Assembly committee. The bill, SB 598, also would prevent the substitution of biosimilars when prescriptions include a "do not substitute" direction.

View Full Article in:

California Healthline · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park